43
Inhibitors of MALT1 for the Treatment of Lymphomas
Weill Cornell Medicine
Small molecule
Oncology
Hit To Lead or Lead Optimization
Technology Summary
Four lead compounds that inhibit MALT1 protease for the treatment of B cell lymphomas. Two have been tested in mouse models of diffuse large B-cell lymphoma (DLBCL).
Background
Unmet Need
Selective MALT1 inhibitors as lead therapeutic candidates for ABC DLBCL
Technology Overview
The Melnick lab and its collaborators have developed four lead compounds from discovery campaigns.
Ari M. Melnick
• US 9592223 B2 (2017.03.14)
Patent Family: KR, US, EP, JP, CN, CA, AU
• US 10711036 B2 (2020.07.14)
Patent Family: US, EP, JP
• US 10689366 B2 (2020.06.23)
Patent Family: US, EP, JP
• US 11248007 B2 (2022.02.15)
Patent Family: US, EP, JP
• "Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth". Fontan, L. et al. Journal of Clinical Investigation 2018, 128(10), 4397–4412
• "Quinoline and thiazolopyridine allosteric inhibitors of MALT1". Scott at al. Bioorganic & Medicinal Chemistry Letters 2019
• "Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth". Fontan at al. Journal of Clinical Investigation 2018